Laparoscopically Resected Composite Pheochromocytoma-Ganglioneuroma

Na Rae Kim, Taeun Kim¹, Jeong Nam Lee², Young Sil Eom³, Dong Hae Chung, Sanghui Park, Hyun Yee Cho
Department of Pathology, Gachon University Gil Hospital, Incheon; Department of Pathology¹, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of Surgery², Division of Endocrinology and Metabolism, Department of Internal Medicine³, Gachon University Gil Hospital, Incheon, Korea

Composite pheochromocytoma-ganglioneuroma is one of the mixed neuroendocrine-neural tumors composed of pheochromocytoma and other neural crest derivatives. To date, less than 50 cases of composite pheochromocytoma have been reported, and about 70% of the accompanying tumors were ganglioneuromas. Here, we describe six cases of composite pheochromocytoma-ganglioneuromas in five men and one woman, aged 33 to 64. The size of the tumors ranged from 3.0 to 11.0 cm, and four out of the six presented with intermittent onset of hypertension, palpitation, or dizziness. Microscopically, each tumor was composed of large pleomorphic shaped chromaffin cells arranged in the Zellballen patterns characteristic of pheochromocytoma, and they were mixed with clusters of mature ganglion cells and bundles of spindle-shaped Schwann cells characteristic of ganglioneuroma of variable proportions. All were successfully treated laparoscopically, and none were associated with multiple endocrine neoplasm syndrome or neurofibromatosis.

Preoperative diagnosis of a composite pheochromocytoma-ganglioneuroma is impossible because of the low incidence rate, and the radiological findings and symptoms are similar to those of typical pheochromocytomas. Although the significance of microscopic detection of the nonpheochromocytoma component from pheochromocytoma has not yet been clarified, microscopic identification of the composite pheochromocytoma-ganglioneuroma is important because cumulative cases are used in an effort to predict the behavior of this composite tumor. (Endocrinol Metab 26:340-344, 2011)

Key Words: Adrenal glands, Composite pheochromocytoma-ganglioneuroma

INTRODUCTION

Mixed adrenal tumors composed of more than one cell type are uncommon; they are called composite pheochromocytomas [1] and corticomedullary mixed tumors [2]. This type of pheochromocytoma is called composite or mixed, depending on whether pheochromocytoma and nonpheochromocytomatous combined components are of the same or different embryonic origin. About 50 cases of composite pheochromocytoma have been published in the English medical literature [3]. Composite pheochromocytoma is a well-defined neoplasm of the medulla and the tumor consists of both endocrine and neural components. Histologically, the endocrine portion is that of a pheochromocytoma, whereas the neural portion has been reported as ganglioneuroma, ganglioneuroblastoma, neuroblastoma, neuroendocrine carcinoma or malignant peripheral nerve sheath tumor [4]. Pheochromocytoma is usually characterized by a catecholaminergic effect with hypertension, whereas ganglioneuroma is a rare mature neuroblastic tumor that is typically nonmetabolically active, and so it is usually asymptomatic [5,6].

To date, less than 50 cases of composite pheochromocytoma have been reported [1-6], and two Korean cases of composite pheochromocytomas have been reported in the English and Korean literature [5,6]. Here, we report additional six cases of unusual tumor of the adrenal gland and the tumor exhibited a mixed phenotype composed of cells of adrenal medullary and neural lineages.

CASE REPORT

1. Clinical summary
Case 1 was a 54-year-old normotensive woman visited an endo-
crinology clinic of Gachon University Gil Hospital in February 2010. She previously had visited the hospital in May 2000 to evaluate incidentally found right adrenal mass. Abdominal computed tomography (CT) showed a 4 cm-sized well defined heterogeneous attenuated soft tissue mass in right adrenal gland (Fig. 1A). She did not complain any subjective symptoms and wanted to be regular follow-up. During 10 years of preoperative follow-up period, she experienced two episodes of headache. Case 2 was a previously healthy 37-year-old man visited an emergency room of Samsung Seoul Hospital in July 2005 for severe headache. He had been suffered from severe headache for one year when hypertension and medication started. At that time, he also undertook a brain magnetic resonance for his severe headache. Abdominal CT taken at the emergency room showed a well-defined 5.0 cm-sized heterogeneous mass at the right adrenal gland (Fig. 1C). Case 4 was a 58-year-old man who visited an emergency room of Samsung Seoul Hospital in January 2008. He had been suffering from headache and dizziness for the previous 2 months although he had been undertaken antihypertensive drugs for the previous 4 years. Abdominal CT revealed a 3.3 cm-sized right enhancing mass with central necrosis and cystic changes at right adrenal gland (Fig. 1D). Case 5 was a previously healthy 50-year-old man. A health screening taken in August 2005 at Samsung Seoul Hospital revealed increased level of 24 hour urine metanephrine was increased in all the 6 cases and the urine VMA level was elevated in cases 2, 3, and 6. But, endocrine profile of blood and/or urine showed increased catecholamines including epinephrine, norepinephrine or dopamine. To control the preoperative hypertension, calcium channel blockers, including bevantolol and nifedipine and alpha-antagonists were administered. All the cases underwent laparoscopic adrenalectomies. During the follow-up period ranging from 3 months to 6 years, their hypertension was controlled without any medication after adrenalectomy. The levels of blood/urine catecholamines returned to normal with no radiologic evidence of metastasis after the operation. The pre- and post-operative the 24 hour analysis of urine VMA and metanephrine were shown in Table 1. All the patients and their families were not associated with neurofibromatosis or multiple endocrine neoplasm (MEN) syndrome.

2. Pathological findings

Grossly, the laparoscopically resected specimens consisted of irregular pieces of firm pinkish tan tissue in cases 2, 3, and 6. A well defined encapsulated oval shaped brownish yellow mass was found in cases 1, 4, and 5. The size of each tumor ranged from 3.0 to 11.0 cm. The cut surface was yellowish brown to mahogany-brown color (Fig. 1E, F). The specimen was received in 10% neutral-buffered formalin and processed routinely. In addition to routine hematoxylin and eosin stains, immunohistochemistry for phosphorylated neurofilament (2F11, 1:100 dilution; Dako, Glostrup, Denmark), S-100 protein (polyclonal, prediluted; Dako), synaptophysin (SY38, prediluted; Dako) and chromogranin A (DAK-A3, prediluted; Dako) were performed on formalin-fixed, paraffin-embedded tissue. Microscopically, the masses were characterized by nests, anastomosing cords and trabeculae of large polygonal cells, i.e., Zellballen pattern (Fig. 2A). Between the nests, large globoid ganglion-like cells in a fibrillary schwannian loose stroma were identified. In the portion of trabeculae of large chromaffin cells, some of them had tiny nucleoli and abundant, basophilic granular cytoplasm, with prominent intracytoplasmatic inclusions (Fig. 2B). Focal melanin-like pigmentation of the chromaffin cells was also noted. Mitotic figures were rare. That portion was diagnosed as pheochromocytoma. The bundles of spindle cells were admixed with the ganglioid cells, and the findings were consistent with ganglioneuroma (Fig. 2C). The ganglioid cells were strongly positive for phosphorylated neurofilament (Fig. 2D) and S-100 protein, while the large chromaffin cells were positive for synaptophysin (Fig. 2E) and chromogranin A with amidixed S-100 protein-positive sustentacular cells (Fig. 2F). The tumors were diagnosed as composite pheochromocytoma-ganglioneuromas. The proportions of ganglioneuroma in cases 1, 2, 3, 4, 5, and 6 comprised from 30%, 40%, 10%, 30%, 50%, and 60%, respectively.
Fig. 1. A. Case 1. Thin section enhanced adrenal computed tomography (CT) shows a well defined round soft tissue mass, which is peripherally well enhanced with heterogeneous low attenuated internal density. B. Case 2. A large well enhancing mass shows central cystic degeneration at the hepatorenal space. The mass also displaces the liver. C. Case 3. CT reveals a 5 cm-sized heterogenous enhancing mass in right adrenal gland. D. Case 4. Postcontrast abdominal CT images show a heterogeneously enhancing right adrenal mass with central cystic changes. E. Case 4. A brownish yellow colored oval mass compresses the surrounding adrenal cortex. Note the fish flesh cut surface and focal cystic changes. F. Case 5. A brown mahogany-colored oval mass shows the central hemorrhagic cystic changes and surrounding thinned adrenal cortex.

Fig. 2. Case 6. A. The mass is composed of majority of pheochromocytoma (upper left) and ganglioneuroma portion (lower and right, H&E stain, × 100). B. The pheochromocytoma portion shows the typical morphology of nests and trabeculae of polygonal shaped chromaffin cells (H&E stain, × 200). C. In the ganglioneuroma portion, the neoplastic ganglion cells have vesicular nuclei with a single prominent nucleolus and amphophilic cytoplasm with granules. Note the fibrillary Schwannian spindle cells in the matrix (H&E stain, × 400). D. The plump ganglion cells of ganglioneuroma portion are stained with phosphorylated neurofilament (phosphorylated neurofilament immunostain, × 400). E. In pheochromocytoma portion, the chromaffin cells are diffusely stained with synaptophysin (synaptophysin immunostain, × 400). F. Immunostain for S-100 protein stains ganglioid cells and Schwannian background (left), while it stains some sustentacular cells of pheochromocytoma (right) (S-100 protein immunostain, × 400).
DISCUSSION

Preoperative detection of a composite pheochromocytoma-ganglioneuroma is difficult because the low incidence of ganglioneuroma and the symptoms are not different from those of typical pheochromocytomas. Pathologically, the chromaffin cells of the pheochromocytoma are more readily highlighted with chromogranin and synaptophysin staining and they are admixed with S-100 protein-positive sustentacular cells [7]. All the tumor cells of the pheochromocytoma portion out of the composite tumor are strongly positive for tyrosine hydroxylase, i.e., the rate-limiting enzyme in catecholamine synthesis, while the ganglioneuroma portion displays neurofilament-positive mature ganglion cells and S-100 protein-positive Schwann cells.

Composite pheochromocytoma-ganglioneuromas are composed of chromaffin cells and the sympathetic ganglion cells [1-6]. The histogenesis of composite adrenal medullary tumors has been attributed to the common embryologic origin of the chromaffin and neuronal cells from the neural crest. To date, less than 50 cases of composite pheochromocytoma-ganglioneuromas have been reported since the first description [8]. The composite tumor has been used to describe tumors that theoretically arise from a common embryologic progenitor, whereas mixed pheochromocytomas designate tumors that have no common embryologic ancestry.

In about 70% of composite adrenal medullary tumors, the accompanying second tumor component was ganglioneuroma. The clinical symptoms associated with composite pheochromocytoma-ganglioneuroma are usually similar to those of ordinary pheochromocytoma, but secretion of vasoactive intestinal polypeptides (VIP) is more common with composite pheochromocytoma-ganglioneuroma compared to the latter [3]. Hypertension and its related symptoms are common in composite pheochromocytoma-ganglioneuroma. Occasional normotensive patients with composite tumors may be explained by the theory of autonomic regulation by ganglioneuroma, and it partially depends on the complex biochemical interaction and proportion of each element [9]. Rarely, watery diarrhea, hypokalemia and achlorhydria syndrome due to a functional VIP-secreting tumor can be observed in patients with composite pheochromocytoma-ganglioneuroma, and vasodilatory action of VIP also contributes the normotension [10]. Commonly observed muscle weakness may be related to associated hypokalemia [11]. Adrenal composite tumor may be incidentally discovered, masquerading as acute relapsing pancreatitis [5]. These composite tumors of the adrenal medulla may be associated with sporadic tumors or as part of neurofibromatosis type I, von Hippel-Lindau disease, MEN 2A and MEN 2B syndromes [12]. The present cases were shown to have no relation to neurofibromatosis, but 6% to 11% of composite pheochromocytomas are associated with genetic conditions. In general, the patients with pheochromocytoma are likely to develop papillary carcinoma, which may be related to the undulatory release of thyroid hormone secondary to circulating catecholamines [6,13]. Albeit rare, these findings should warn the patients to undergo regular examination of the thyroid gland.

Both pheochromocytoma and ganglioneuroma commonly manifests radiologically as a well-defined, smooth or lobulated mass with or without calcification. CT is accurate in the detection of pheochromocytomas. However, nearly one third of all cases show a non-specific appearance that may overlap with the appearance of adrenocortical carcinoma [14]. In the same manner, composite pheochromocytoma and ganglioneuroma shows heterogenous radiologic, gross and microscopic features with varying admixtures of ganglioneuroma and pheochromocytoma components [15].

The clinical significance of microscopically detecting the other component from pheochromocytoma has not yet been clarified.

Table 1. Pre- and postoperative biochemistry including 24 hour urine analysis of the six cases

| Case | Abnormal blood endocrine biochemistry | Urine VMA (reference, < 8 mg/day) | Urine metanephrine (reference, < 45-290 μg/day) |
|------|--------------------------------------|----------------------------------|-----------------------------------------------|
|      |                                      | Preoperative | Postoperative | Preoperative | Postoperative |
| Case 1 | Elevated norepinephrine | 7.61 | 5.78 | 810 | 120 |
| Case 2 | Elevated epinephrine, norepinephrine, metanephrine | 150 | 4.46 | 2,690 | 440 |
| Case 3 | Elevated epinephrine, norepinephrine | 13.7 | 4.4 | 1,657.8 | 182.45 |
| Case 4 | Elevated epinephrine, norepinephrine, dopamine | 6.0 | 5.1 | 315.72 | 75.2 |
| Case 5 | Elevated epinephrine, norepinephrine | 7.7 | 3.2 | 1,033.43 | 35.88 |
| Case 6 | Elevated epinephrine, norepinephrine | 14.5 | 4.6 | 4,450 | 285 |

VMA, vanillylmandelic acid.
because of the paucity of reports. Although there was one case of pheochromocytoma-ganglioneuroma showing hepatic metastasis, the composite pheochromocytomas with only a ganglioneuroma portion behave in the same manner as a classic pheochromocytoma and even when there are neuroblastomatous components because neuroblastomatous elements have low mitotic-karyorrhectic index and absence of N-myc amplification [15-17]. A review by Lam and Lo [18] suggests that the composite tumors are seen in older patients and are bigger than typical pheochromocytomas, which is possible that they are more aggressive than pheochromocytoma alone [10].

Here, all the six cases of composite pheochromocytoma-ganglioneuroma undertook laparoscopic adrenalectomies. Laparoscopic adrenalectomy provides the benefits of a minimally invasive approach, and is regarded to be the surgery of choice for pheochromocytoma, compared to open resection, due to the improved pre-operative hemodynamic stability and the lessened need for post-operative analgesics [18].

SUMMARY

In summary, microscopic identification of a non-pheochromocytomatous component from pheochromocytoma is important because cumulative cases of composite pheochromocytoma-ganglioneuroma may be used to predict the biologic behavior of this rare tumor.

REFERENCES

1. Menon S, Mahajan P, Desai SB: Composite adrenal medullary tumor: a rare cause of hypertension in a young male. Urol Ann 3:36-38, 2011
2. Lau SK, Chu PG, Weiss LM: Mixed cortical adenoma and composite pheochromocytoma-ganglioneuroma: an unusual corticomedullary tumor of the adrenal gland. Ann Diagn Pathol 15:185-189, 2011
3. George DJ, Watermeyer GA, Levin D, Epstein D, Ross IL, Scholz BU, Seshshedi M, Lockerz M, Dittrich C, Shaw J, Krige JE: Composite adrenal pheochromocytoma-ganglioneuroma causing watery diarrhoea, hypokalaemia and achlohydria syndrome. Eur J Gastroenterol Hepatol 22:632-634, 2010
4. Gupta R, Sharma A, Arora R, Vijayaraghavan M: Composite pheochromocytoma with malignant peripheral nerve sheath tumour and rhabdomyosarcomatous differentiation in a patient without von Recklinghausen disease. J Clin Pathol 62:659-661, 2009
5. Choi EK, Kim WH, Park KY: A case of a composite adrenal medullary tumor of pheochromocytoma and ganglioneuroma masquerading as acute pancreatitis. Korean J Intern Med 21:141-145, 2006
6. Ahn J, Lee SE, Chung YJ, Chi KC, Kim MK, Oh YS, Kim J: A case of papillary thyroid cancer and pheochromocytoma with ganglioneuroma. Korean J Med 76:85-89, 2009
7. de Montpréville VT, Masson S, Gharbi N, Dartevelle P, Dulmet E: Paraganglioma with ganglioneuromatous component located in the posterior mediastinum. Ann Diagn Pathol 9:110-114, 2005
8. Khan AN, Solomon SS, Childress RD: Composite pheochromocytoma-ganglioneuroma: a rare experiment of nature. Endocr Pract 16:291-299, 2010
9. Aiba M, Hirayama A, Ito Y, Fujimoto Y, Nakagami Y, Demura H, Shizume K: A compound adrenal medullary tumor (pheochromocytoma and ganglioneuroma) and a cortical adenoma in the ipsilateral adrenal gland. A case report with enzyme histochemical and immunohistochemical studies. Am J Surg Pathol 12:559-566, 1988
10. Mahajan H, Lee D, Sharma R, Chin P, Watt WH, McBride G, Bilous M: Composite pheochromocytoma-ganglioneuroma, an uncommon entity: report of two cases. Pathology 42:295-298, 2010
11. Onozawa M, Fukushima T, Minoguchi M, Takahata M, Yamamoto Y, Miyake T, Kanagawa K, Kanda M, Mekawa I: Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1. Jpn J Clin Oncol 35:559-563, 2005
12. Charfi S, Ayadi L, Ellozze S, Ghorbel R, Khairi A, Gouiaa N, Bahri I, Fakhfakh I, Makni S, Sellami-Boudawra T: Composite pheochromocytoma associated with multiple endocrine neoplasia type 2B. Ann Pathol 28:225-228, 2008
13. Kragel PJ, Johnston CA: Pheochromocytoma-ganglioneuroma of the adrenal. Arch Pathol Lab Med 109:470-472, 1985
14. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR: The clinically apparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309-340, 2004
15. Lam KY, Lo CY: Composite pheochromocytoma-ganglioneuroma of the adrenal gland: an uncommon entity with distinctive clinicopathologic features. Endocr Pathol 10:343-352, 1999
16. Lisewski D, Ryan S, Lim EM, Frost F, Nguyen H: Concomitant composite adrenal pheochromocytoma, multiple gastric stromal tumours and pseudohyperplasmod in a patient with von Recklinghausen’s disease. Int Surg Oncol 3:11, 2006
17. Comstock JM, Willmore-Payne C, Holden JA, Goffin CM: Composite pheochromocytoma: a clinicopathologic and molecular comparison with ordinary pheochromocytoma and neuroblastoma. Am J Clin Pathol 132:69-73, 2009
18. Kim HH, Kim GH, Sung GT: Laparoscopic adrenalectomy for pheochromocytoma: comparison with conventional open adrenalectomy. J Endourol 18:251-255, 2004

http://www.enm-kes.org
http://dx.doi.org/10.3803/EnM.2011.26.4.340